Quest Diagnostics®

Respiratory testing portfolio (COVID-19/flu/RSV)

Antibody (serology)

Test name	Test code	CPT® codes
SARS-CoV-2 Total Antibody, Spike, Semi-Quantitative	39820	86769
SARS-CoV-2 Antibody (IgG), Nucleocapsid, Qualitative	39749	86769

A positive SARS-CoV-2 spike antibody result indicates an immune response to a recent/prior infection or vaccination.

A positive SARS-CoV-2 nucleocapsid antibody result indicates an immune response to a recent or prior infection.

Single molecular (PCR/NAAT) component tests

Test name	Test codes	CPT® codes
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	39448	87635
Influenza A and B RNA, Qualitative Real-Time PCR	16086	87502
Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR	16047	87634

Combination molecular (PCR/NAAT) panels

Test name	Test code	CPT® codes
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT Includes: SARS-CoV-2 RNA (COVID-19), Qualitative NAAT (test code 39448) and Influenza A and B RNA, Qualitative Real-Time PCR (test code 16086)	31688	87636
SARS-CoV-2 RNA (COVID-19) and Influenza A/B and RSV RNA, Qualitative NAAT Includes: SARS-CoV-2 RNA (COVID-19), Qualitative NAAT (test code 39448); Influenza A and B RNA, Qualitative Real-Time PCR (test code 16086); and Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR (test code 16047)	39816	87637
Influenza A and B and RSV RNA, Qualitative, Real-Time RT-PCR Includes: Influenza A and B RNA, Qualitative Real-Time PCR (test code 16086) and Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR (test code 16047)	91989	87631

Visit our test directory to learn more about our complete portfolio of respiratory infection tests at **https://testdirectory.questdiagnostics.com**

Combination molecular (PCR/NAAT) panels (continued)

	Test name	Test code	CPT® codes
Panel name	**Respiratory Viral Panel, PCR** The Respiratory Viral Panel, PCR includes the components below:	95512	87633
Components available for individual order	SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	39448	87635
	Adenovirus DNA, Qualitative, Real-Time PCR	16046	87798
	Rhinovirus RNA, Real-Time PCR	40035	87798
	Enterovirus RNA, Qualitative, Real-Time PCR	15082	87498
	Human Metapneumovirus RNA, Qualitative, Real-Time PCR	40034	87798
	Influenza A and B RNA	16086	87502
Other panel components	Influenza A subtype H1 Influenza A subtype H3		
	HPIV 1 HPIV 2 HPIV 3 HPIV 4	91228	87631
	Human respiratory syncytial virus (HRSV) A HRSV B		

	Test name	Test code	CPT® codes
Panel name	**Respiratory Pathogen Panel** The Respiratory Pathogen Panel includes the components below:	37444	87633 87486 87581
Components available for individual order	SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	39448	87635
	HPIV 1 HPIV 2 HPIV 3 HPIV 4	91228	87631
	Rhinovirus RNA, Real-Time PCR	40035	87798
	Enterovirus RNA, Qualitative, Real-Time PCR	15082	87498
	HMPV	40034	87798
	Adenovirus DNA, Qualitative, Real-Time PCR	16046	87798
	Chlamydophila pneumoniae, DNA, Qualitative, Real-Time PCR	16003	87486
	Mycoplasma pneumoniae DNA, Qualitative, Real-Time PCR	15498	87581
	Influenza A and B RNA, Qualitative Real-Time PCR	16086	87502
Other panel components	Coronavirus 229e Coronavirus OC43 Coronavirus NL63 Coronavirus HKU1 Influenza A subtype H1 Influenza A subtype H3		

HPIV, human parainfluenza virus.

Test codes may vary by location. Please contact your local laboratory for more information.

Panel components may be ordered separately.

The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

The IgG antibody tests are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the test may occur due to cross-reactivity from pre-existing antibodies or other possible causes. The results of this semi-quantitative test should not be interpreted as an indication or degree of immunity or protection from reinfection.

- The Quest Diagnostics molecular test, the other authorized molecular tests (together the "molecular tests"), the COVID/Flu molecular test, the COVID/Flu/RSV test, and the antibody test (together "the tests") have not been FDA cleared or approved;
- The tests have been authorized by FDA under an EUA for use by authorized laboratories;
- The molecular tests have been authorized only for the unsupervised self-collection and maintenance of nasal specimens for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens;
- The COVID/Flu molecular test and self-collection kit have been authorized only for the unsupervised self-collection and maintenance of nasal specimens as an aid in detection of nucleic acid from SARS-CoV-2 and influenza A virus and influenza B virus, not for any other viruses or pathogens;
- The COVID/Flu/RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
- The antibody test has been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and,
- The tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Image content features models and is intended for illustrative purposes only

QuestDiagnostics.com